Erythematous Papular Rash: A Dermatological Feature of COVID-19

Gonçalves, Catarina; Carreira, Nuno Reis; Passos, Dúlio Teixeira; Barbosa, Ana; Baltazar, Ana Maria; Wahnon, Alexandra; Abrantes, Ana Mafalda; Garrido, Pedro; Ferreira, Teresa; Silva, Marisa Teixeira; Alvoeiro, Lourdes

doi:10.12890/2020_001768

Cited by 5 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these, 34 were selected for full text review based on their title and abstract. Full text screening resulted in the final selection of 25 articles (Figure 1), [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] reporting 26 patients with urticaria and/or angioedema and COVID-19 infection and their management plan and/or response to management. Table 1 includes the summarized key findings of the studies included in this review.…”

Section: Resultsmentioning

confidence: 99%

Management of urticaria in COVID ‐19 patients: A systematic review

Abuelgasim

Dona

Sondh

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Objectives The global pandemic COVID‐19 has resulted in significant global morbidity, mortality and increased healthcare demands. There is now emerging evidence in of patients experiencing urticaria. We sought to systematically review current evidence, critique the literature and present out findings. Methods Allowing PRISMA guidelines, a comprehensive literature search was carried out with Medline, EMBASE, Scopus, Cochrane, and Google Scholar, using key MeSH words, which include “COVID‐19,” “Coronavirus”, “SARS‐Cov‐2”, “Urticaria,” “Angioedema,” “Skin rash” up to August, 01 2020. The key inclusion criteria were articles that reported on urticaria and/or angioedema due to COVID‐19 infection and reported management and outcome. Studies were excluded if no case or cohort outcomes were observed. Results Our search returned 169 articles, 25 of which met inclusion criteria. All studies were case reports, reporting 26 patients with urticaria and/or angioedema and COVID‐19 infection and their management and/or response. Majority of patients (n=16, 69%) were over 50 years old. However, urticaria in the younger ages was not uncommon, with reported case of 2 months old infant. Skin lesions resolved from less than 24 hours to up to 2 weeks following treatment with antihistamines and/or steroids. There have been no cases of recurrent urticaria or cases non‐responsive to steroids. Conclusions Management of urticarial in COVID‐19 patients should involve antihistamines. Low dose prednisolone should be considered on an individualised basis. Further research is required in understanding urticarial pathogenesis in COVID‐19. This will aid early diagnostic assessment in patients with high index of suspicion and subsequent management in the acute phase. This article is protected by copyright. All rights reserved.

show abstract

Section: Resultsmentioning

confidence: 99%

Management of urticaria in COVID ‐19 patients: A systematic review

Abuelgasim

Dona

Sondh

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…36 A case report by Mazan et al described the development of Itchy, maculopapular rash with nontender erythematous macules and papules following 10 days of lopinavir/ritonavir administration. 37 In spite of this, in case series with the patients taking no new medications, the maculopapular rash has been recognized, hinting that these lesions may not just be associated with drugs. 38 As can be observed, Covid-19 related maculopapular rash can occur in various appearances, affect patients of all ages and genders, and affect any part of the body.…”

Section: Secondary Cutaneous Lesions Expedited By the Systemic Effect Ofmentioning

confidence: 99%

Maculopapular skin eruptions associated with Covid‐19: A systematic review

Shams

Rathore²,

Anvekar

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

In this systematic review, we anticipated in summarizing clinical features, histopathological hallmarks, and possible pathology behind the maculopapular skin eruptions occurring in Covid-19 patients. A literature search was executed using MEDLINE/ PubMed and Embase databases for articles published till 20 November 2020. All eligible articles including observational studies, case reports, and case series reporting the maculopapular skin lesion in Covid-19 patients were included. Data were obtained for 354 Covid-19 patients presenting with maculopapular lesions from 40 studies. The mean age of these patients was 53 years, and with 42% of them being male. These maculopapular lesions differed considerably in terms of distribution and appearance, ranging from diffuse erythematous maculopapular lesions to scattered erythematous macules coalescing into papules to maculopapular lesions in plaques. The mean duration of the lesion was 8 days. These lesions were frequently localized on trunks and extremities. Superficial perivascular dermatitis with lymphocytic infiltrate was a histopathological hallmark of these lesions. As these skin lesions may have a possible association with diagnosis, management, prognosis, and severity of the disease, all health practitioners need to be well acquainted with these Covid-19 skin lesions. Also, in the middle of this worldwide pandemic, early identification of this eruption may help manage this infection's further spread.

show abstract

“…Hasta la fecha, la infección por SARS-CoV-2 ha afectado a 468 millones de personas y se han reportado más de 6 millones de muertes [10]. Tiene un espectro clínico muy amplio, y puede variar desde una infección asintomática, pasando por una forma leve dada por fiebre, mialgias, cefalea, anosmia y ageusia, hasta una forma severa que puede incluir síndrome de dificultad respiratoria aguda, daño cardíaco, sepsis y falla renal aguda [11,12]. Inicialmente, los síntomas reconocidos eran solo los respiratorios, los cuales pueden ser tan severos que requieran ventilación, y en algunos casos, causen la muerte [13].…”

Section: Introductionunclassified

“…Inicialmente, los síntomas reconocidos eran solo los respiratorios, los cuales pueden ser tan severos que requieran ventilación, y en algunos casos, causen la muerte [13]. Pero a medida que el tiempo transcurre y se conoce más acerca de COVID-19, se han comenzado a asociar otros síntomas a la enfermedad; entre ellos, las manifestaciones cutáneas [14], las cuales se diagnostican cada vez con mayor frecuencia, y se ha encontrado que varían en su prevalencia de acuerdo con la ubicación geográfica [12,15,16].…”

Section: Introductionunclassified

Pitiriasis rosada como manifestación dermatológica de infección por SARS-CoV-2: a propósito de un caso

et al. 2022

View full text Add to dashboard Cite

Las manifestaciones cutáneas relacionadas a la infección por el coronavirus SARS-CoV-2, causante de COVID-19, se han descrito entre el 0,2% y 20,4% de las personas que cursan con esta enfermedad. Las más frecuentemente descritas son: lesiones maculopapulares (47%), lesiones acrales eritematosas con vesículas o pústulas (pseudoperniosis) (19%), urticariales (19%), lesiones vesiculosas (9%) y livedo/necrosis (6%). En particular, la pitiriasis rosada es una dermatosis autolimitada de etiología desconocida, sin embargo, se ha visto asociada a la infección por SARS-CoV-2, con algunos reportes de casos en la literatura. El mecanismo fisiopatológico de las lesiones cutáneas en COVID-19 no es claro, y se han planteado algunas teorías, entre las cuales está el papel que juega la enzima convertidora de angiotensina 2 (ACE2) utilizada por el virus para infectar las células, los infiltrados linfocíticos, los depósitos de factores del complemento en la piel, y la reactivación de virus latentes como los herpes virus humanos. Se presenta el caso de una paciente con pitiriasis rosada asociada a COVID-19 y se describen los casos reportados hasta la fecha.

show abstract

Erythematous Papular Rash: A Dermatological Feature of COVID-19

Cited by 5 publications

References 8 publications

Management of urticaria in COVID ‐19 patients: A systematic review

Management of urticaria in COVID ‐19 patients: A systematic review

Maculopapular skin eruptions associated with Covid‐19: A systematic review

Pitiriasis rosada como manifestación dermatológica de infección por SARS-CoV-2: a propósito de un caso

Contact Info

Product

Resources

About